Status:
UNKNOWN
Molecular Diagnostic Platform for AML
Lead Sponsor:
PETHEMA Foundation
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
18-99 years
Brief Summary
This will be a translational study without any therapeutic intervention, for the purpose of analyzing the diagnostic and molecular results / characterization of adult patients with AML, regardless of ...
Detailed Description
This will be a multicenter, translational study without any therapeutic intervention. It will be conducted at 7 central laboratories (Hospital Universitari i Politècnic La Fe, Hospital Universitario d...
Eligibility Criteria
Inclusion
- Have voluntarily given informed consent for the sending and processing of biological specimens, as well as for the analysis and reporting of the results on the mutation status of their AML.
- Age greater than or equal to 18 years.
- Morphological diagnosis of AML or acute leukemia of ambiguous lineage according to WHO criteria at diagnosis, relapse or resistance.
Exclusion
- Inability of the patient or his/her legal representative to understand and voluntarily sign the informed consent form
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04446741
Start Date
October 1 2019
End Date
October 1 2022
Last Update
September 5 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Reina Sofía
Córdoba, Spain
2
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Spain
3
Hospital Doce de Octubre
Madrid, Spain
4
Clínica Universidad de Navarra
Pamplona, Spain